Insurance rejections as variable consideration · IFRS 15

In plain words

Insurers routinely reject part of a hospital's claims. The question is whether to record full revenue and treat rejections later as bad debt. Expected rejections are variable consideration, so at billing revenue is reduced to the amount highly probable not to reverse, using payor- and procedure-specific rejection history. Differences when remittances arrive adjust revenue, not bad debt expense. Genuine credit risk on approved amounts is assessed separately under IFRS 9.

Why it matters

Insurance rejections are routine and material in volume; treating them as bad debt after full recognition instead of as variable consideration at inception overstates revenue, receivables and profit in the period of billing, then produces large, lumpy write-offs later that mislead trend analysis. Correctly constraining the estimate from day one keeps revenue and ECL exposure realistic and comparable period to period.

Diagnostic questions

Does the entity have at least two to three years of reliable rejection-rate history segmented by payor and procedure code? Is the population of claims large and homogeneous enough to justify an expected-value estimate, or is it a small set of large, individually negotiated claims better suited to a most-likely-amount estimate? Is the rejection constraint being reassessed and trued up through revenue as remittance advices are received, rather than deferred to a later bad-debt write-off?

Recognition

1) Build a payor- and procedure-specific historical rejection rate using at least 2-3 years of remittance data. 2) At the point of billing, reduce the transaction price by the expected rejection rate to arrive at the amount highly probable not to reverse significantly (the constraint). 3) Recognize revenue net of this constrained estimate, not the full billed amount. 4) As actual remittance advices are received each period, true up the estimate through a cumulative catch-up adjustment to revenue (not to bad debt expense). 5) Separately monitor genuine credit risk (payor insolvency/slow payment on approved amounts) under IFRS 9, keeping it distinct from the pricing-driven rejection estimate. 6) Recalibrate the historical rate periodically, especially for new payors, new procedure codes or regulatory coding changes.

Measurement

Use the expected value method (probability-weighted average of possible rejection outcomes) where a large portfolio of similar claims by payor and procedure exists; use the most likely amount for a small number of large, individually assessed claims or unique disputes. Apply the constraint so that only the amount highly probable not to reverse significantly is included in the transaction price. Re-measure at each reporting date as actual remittances are received, updating both the rate and the population it is applied to.

Presentation & disclosure

Disclose the nature of variable consideration arising from insurer rejections and the estimation method (expected value vs. most likely amount); disclose the amount of cumulative catch-up revenue adjustments recognized in the period from changes in rejection estimates; disaggregate rejection-driven price reductions from IFRS 9 credit-risk allowances in the notes; disclose the payor concentration if a small number of payors drive most of the estimate.

Common mistakes

Recognizing 100% of billed insurance revenue and later writing off rejections as bad debt expense instead of as a revenue reduction at inception
using a flat, unreviewed rejection percentage without updating it against actual experience by payor
not distinguishing rejections due to pricing/coding disputes (variable consideration, IFRS 15) from genuine payor credit risk on approved amounts (IFRS 9)
applying a single company-wide rejection rate across payors with very different denial behavior
failing to true up estimates promptly once remittance data is available, leaving stale accruals on the books.

Simple example

A clinic bills an insurer SAR 200,000 in a month; based on 3 years of history it expects a 12% rejection rate (SAR 24,000), so it recognizes net revenue of SAR 176,000.
At billing: Dr Contract asset/Receivable - insurer 176,000 / Cr Patient service revenue 176,000.
When remittance advices are later received showing actual rejections of only SAR 20,000 (i.e. SAR 180,000 approved), the estimate is trued up: Dr Contract asset/Receivable - insurer 4,000 / Cr Patient service revenue 4,000 (cumulative catch-up for the SAR 4,000 favorable variance).
On collection of the approved SAR 180,000: Dr Cash 180,000 / Cr Trade receivable - insurer 180,000.

Professional judgment

Estimating the constrained rejection rate for new payors, new procedure codes, or after a regulatory coding change without sufficient history is genuinely judgmental, practitioners often blend the entity's own limited data with sector benchmarks, and should document the basis and revisit it at least quarterly. A further grey area is deciding whether to use expected value (appropriate for a large homogeneous portfolio of similar claims) versus the most likely amount (better for a concentrated set of large, individually negotiated claims), since the two methods can produce materially different constrained estimates.

Source basis

IFRS 15 · Revenue from Contracts with Customers

Paragraph references

IFRS 15.53IFRS 15.56–57IFRS 15.59

Verified against the official standard texts used in the IFRS Expert skill.

IFRS 15 Revenue from Contracts with Customers

Issued: 28 May 2014 · Effective: 1 January 2018

Related issues

Educational and navigation content only. Not professional advice. Does not reproduce official IFRS/IAS text. Consult the authoritative standards and qualified professionals; professional judgment may still be required.